StockData
MoonLake Immunotherapeutics logo

MoonLake Immunotherapeutics (MLTX) stock

MLTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$10.79−0.46 (-4.09%)

Close on Nov 18, 2026Market cap $918.30MP/E –Yield –

MoonLake Immunotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

MoonLake Immunotherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$225.18M. For fiscal 2025 it was -$196.04M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$196.04M–
FY2024Dec 31, 2024-$117.11M–
FY2023Dec 31, 2023-$43.06M–
FY2022Dec 31, 2022-$55.91M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$55.56M–
Q1 FY2026Mar 31, 2026-$66.29M–
Q4 FY2025Dec 31, 2025-$58.79M–
Q3 FY2025Sep 30, 2025-$44.54M–
Q2 FY2025Jun 30, 2025-$54.53M–
Q1 FY2025Mar 31, 2025-$38.18M–
Q4 FY2024Dec 31, 2024-$48.65M–
Q3 FY2024Sep 30, 2024-$25.41M–
Q2 FY2024Jun 30, 2024-$27.89M–
Q1 FY2024Mar 31, 2024-$15.16M–
Q4 FY2023Dec 31, 2023-$12.63M–
Q3 FY2023Sep 30, 2023-$9.25M–
Q2 FY2023Jun 30, 2023-$12.16M–
Q1 FY2023Mar 31, 2023-$9.02M–
Q4 FY2022Dec 31, 2022-$11.60M–
Q3 FY2022Sep 30, 2022-$9.35M–
Q2 FY2022Jun 30, 2022-$20.76M–
Q1 FY2022Mar 31, 2022-$14.20M–
Q3 FY2021Sep 30, 2021-$2.03M–

More MoonLake Immunotherapeutics figures

See a number that looks wrong?